news

CUPERTINO, Calif., April 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2001. The company’s net loss attributable to common stockholders for the three months ended March 31, 2001 was $4.9 million or 11 cents per share, compared to $4.7 million, or 71 cents per share, […]

CUPERTINO, Calif., April 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has acquired Southern BioSystems, Inc. (“SBS”), a privately held company located in Birmingham, Alabama. SBS develops, manufactures and sells biodegradable polymer and non-polymer drug delivery systems. SBS also provides bulk supply of biodegradable polymer for seven FDA approved products sold by

CUPERTINO, Calif., April 24 /PRNewswire Interactive News Release/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, April 30th, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., April 3 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dennis M. Fisher, M.D. has been promoted to the position of Vice President for Medical Affairs. Dr. Fisher joined DURECT in June 2000 as Medical Director. Dr. Fisher, previously Professor of Anesthesia and Pediatrics at the University of California San Francisco, has

CUPERTINO, Calif., March 27 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has a long-term supply agreement with Mallinckrodt, a global manufacturer and marketer of specialty medical products. Mallinckrodt will supply DURECT’s clinical and commercial requirements for sufentanil, a potent opioid analgesic and critical component of the company’s lead product DUROS sufentanil, for

CUPERTINO, Calif., March 9 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed patient enrollment of its Phase II clinical trial for the company’s lead product, DUROS sufentanil. Over 50 patients at 10 clinical centers were enrolled in the trial more than one-quarter ahead of schedule. DURECT anticipates meeting with the

CUPERTINO, Calif., March 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Armand P. Neukermans Ph.D. to its Board of Directors. Dr. Neukermans is currently Chief Technical Officer of the Xros division at Nortel Networks. Dr. Neukermans has over 30 years of experience in the field of electrical and mechanical engineering. Since

CUPERTINO, Calif., March 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 1st Annual Salomon Smith Barney Specialty Pharmaceuticals Conference to be held March 9, 2001

CUPERTINO, Calif., Feb. 16 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000 and reports strong progress in the company’s business operations. The company reiterated its accelerated progress in the Phase II clinical trials for DUROS sufentanil and announced that it expects to complete

CUPERTINO, Calif., Feb. 15 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000. The Company’s net loss attributable to common stockholders for the three months ended December 31, 2000 was $4.9 million or 11 cents per share, compared to a net loss of $3.6